NAMFERO Trademark

Trademark Overview

On Monday, February 8, 2021, a trademark application was filed for NAMFERO with the United States Patent and Trademark Office. The USPTO has given the NAMFERO trademark a serial number of 90518812. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Monday, September 16, 2024. This trademark is owned by Purdue Pharma L.P.. The NAMFERO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Pharmaceuticals, namely, opioid antagonists; Syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Syringes filled with opioid antagonists; Injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectors filled with opioid antagonists; Injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectable pharmaceuticals, namely, opioid antagonists
namfero

General Information

Serial Number90518812
Word MarkNAMFERO
Filing DateMonday, February 8, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateMonday, September 16, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 18, 2022

Trademark Statements

Goods and ServicesPharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Pharmaceuticals, namely, opioid antagonists; Syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Syringes filled with opioid antagonists; Injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectors filled with opioid antagonists; Injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; Injectable pharmaceuticals, namely, opioid antagonists

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, May 13, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePurdue Pharma L.P.
Party Type20 - Owner at Publication
Legal Entity Type13 - Limited Partnership
AddressStamford, CT 06901
Party NamePurdue Pharma L.P.
Party Type10 - Original Applicant
Legal Entity Type13 - Limited Partnership
AddressStamford, CT 06902

Trademark Events

Event DateEvent Description
Thursday, February 11, 2021NEW APPLICATION ENTERED
Friday, February 26, 2021TEAS VOLUNTARY AMENDMENT RECEIVED
Thursday, May 13, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, May 27, 2021ASSIGNED TO LIE
Tuesday, June 1, 2021ASSIGNED TO LIE
Wednesday, June 2, 2021PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Tuesday, August 31, 2021ASSIGNED TO EXAMINER
Wednesday, September 1, 2021NON-FINAL ACTION E-MAILED
Wednesday, September 1, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, September 1, 2021NON-FINAL ACTION WRITTEN
Wednesday, December 8, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, December 9, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, December 8, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, December 10, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 29, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 18, 2022PUBLISHED FOR OPPOSITION
Tuesday, January 18, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 15, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 16, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, August 16, 2022SOU EXTENSION 1 FILED
Tuesday, August 16, 2022SOU EXTENSION 1 GRANTED
Thursday, August 18, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 8, 2023SOU TEAS EXTENSION RECEIVED
Friday, September 8, 2023SOU EXTENSION 3 GRANTED
Friday, March 3, 2023SOU TEAS EXTENSION RECEIVED
Friday, March 3, 2023SOU EXTENSION 2 FILED
Friday, March 3, 2023SOU EXTENSION 2 GRANTED
Tuesday, March 7, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 8, 2023SOU EXTENSION 3 FILED
Tuesday, September 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 12, 2024SOU EXTENSION 4 GRANTED
Wednesday, March 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 16, 2024SOU TEAS EXTENSION RECEIVED
Monday, September 16, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 16, 2024SOU EXTENSION 5 GRANTED
Monday, September 16, 2024SOU EXTENSION 5 FILED
Tuesday, March 12, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, March 12, 2024SOU EXTENSION 4 FILED

Related Keywords

namfero opioid pharmaceuticals antagonists filled disorders treatment reversal overdose injectable injectors